Understanding Liver Dysfunction After Stem Cell Transplant
This study is looking at how liver problems (liver dysfunction) develop in people who have had a hematopoietic stem cell transplant (HSCT). HSCT is a treatment for many cancers and other illnesses. Researchers want to understand why some people develop liver problems after this transplant and how existing liver conditions might affect the transplant's outcome. They will observe 500 participants, aged 3 to 90, who are being considered for an HSCT. The main goal is to see if people with liver disease before their transplant are more likely to die or have severe liver problems within 91 days after the transplant. This is an observational study, meaning no specific interventions are being tested.
- Study design
- This is an observational study with a planned enrollment of 500 participants. It is designed to understand the natural progression of liver dysfunction after transplant.
- What's involved
- You would have 11 study visits over 4 years, with most visits occurring in the first year after your transplant.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcomes, such as death or severe liver problems, will be measured 91 days after the transplant.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Theo Heller, M.D. · PRINCIPAL_INVESTIGATOR · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Death or total bilirubin >=4 at 91 days after the transplant91 days after transplant
To determine whether, at 91 days after transplant, patients with liver disease at transplant are more likely to have died or have a total bilirubin \>=4 than those without liver disease at transplant.
- Mortality rate91 days after transplant
To determine whether, at 91 days after transplant, patients with liver disease at transplant are more likely to have died or have a total bilirubin \>=4 than those without liver disease at transplant.